Literature DB >> 6183343

Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies.

J H Mathews, J T Roehrig.   

Abstract

We have previously characterized seven unique antigenic epitopes on the two envelope glycoproteins of the Venezuelan equine encephalomyelitis (VEE) virus vaccine strain, TC-83, by using monoclonal antibodies. The in vitro function of virus neutralization was primarily associated with one epitope on the gp56 (gp56c). To determine which epitopes were important in protecting animals from VEE infection, purified monoclonal antibodies were inoculated i.v. into 3-wk-old Swiss mice. Twenty-four hours later these animals were challenged i.p. with 100 IPLD50 of virulent VEE virus (Trinidad donkey). High-avidity anti-gp56c, anti-gp50b, anti-gp50c, and anti-gp50d monoclonal antibodies protected animals from virus challenge. Rabbit antisera to the gp56 and the gp50 glycoproteins were also effective in protecting mice from challenge with virulent VEE virus. Less antibody was needed to protect animals if the antibody was directed against the critical neutralization site. Less avid antibodies to the gp56c and gp50b epitopes demonstrated little or no protection in vivo. Protection, therefore, appeared to be a function of the passive antibody's specificity, avidity, and ability to bind to virion antigenic determinants topologically proximal to the critical neutralization site.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183343

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.

Authors:  Michael D Parker; Marilyn J Buckley; Vanessa R Melanson; Pamela J Glass; David Norwood; Mary Kate Hart
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Identification of antigenically important domains in the glycoproteins of Sindbis virus by analysis of antibody escape variants.

Authors:  E G Strauss; D S Stec; A L Schmaljohn; J H Strauss
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

3.  Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins.

Authors:  Andrey A Kolokoltsov; Scott C Weaver; Robert A Davey
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Antibody-selected variation and reversion in Sindbis virus neutralization epitopes.

Authors:  D S Stec; A Waddell; C S Schmaljohn; G A Cole; A L Schmaljohn
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

5.  Early activation of the host complement system is required to restrict central nervous system invasion and limit neuropathology during Venezuelan equine encephalitis virus infection.

Authors:  Christopher B Brooke; Alexandra Schäfer; Glenn K Matsushima; Laura J White; Robert E Johnston
Journal:  J Gen Virol       Date:  2011-12-28       Impact factor: 3.891

6.  Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies.

Authors:  Jason Porta; Joyce Jose; John T Roehrig; Carol D Blair; Richard J Kuhn; Michael G Rossmann
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

Review 7.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

8.  Humanized antibodies for antiviral therapy.

Authors:  M S Co; M Deschamps; R J Whitley; C Queen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

9.  Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo.

Authors:  L Lefrancois
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

10.  Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge.

Authors:  R M Kinney; J J Esposito; J H Mathews; B J Johnson; J T Roehrig; A D Barrett; D W Trent
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.